Abdel-Razik et al. reported that patients with NASH demonstrated significantly reduced proinflammatory cytokine and ALT levels and lower NAFLD-liver fat scores after rifaximin therapy (1,100 mg/day for six months) (91). Here, GPT is linked to metabolic dysfunction-associated steatohepatitis.